Autres langues Coya Therapeutics, Inc.

Actions

COYA

US22407B1089

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 24/05/2024			Varia. 5j.	Varia. 1 janv.
7,91 ^USD	-2,94%		-9,39%	+6,75%

20/05	Coya Therapeutics reçoit un investissement en actions de 5 millions de dollars de la part de l'Alzheimer's Drug Discovery Foundation	MT
09/05	Coya Therapeutics, Inc. présente ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 in Patients with Alzheimer's disease	23/05
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease	22/05
Coya Therapeutics Receives $5 Million Equity Investment from Alzheimer's Drug Discovery Foundation	20/05
Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation (ADDF)	20/05
Coya Therapeutics, Inc. announced that it expects to receive $4.999997 million in funding from Alzheimers Drug Discovery Foundation	17/05
Coya Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results	09/05
Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium	26/04
Coya Therapeutics to Participate in the Mizuho Neuroscience Summit	22/04
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit	18/04
Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium	08/04
Coya Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results	19/03
Coya Therapeutics to Participate in BTIG Fireside Discussion	12/03
Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference	12/03
Coya Therapeutics, Inc. Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference	12/03
Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia at the AD/PD 2024 Conference	07/03
Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference	06/03
Coya Therapeutics to Present Data on Immune System and Regulatory T cell Contributions in Frontotemporal Dementia Patients at AD/PD 2024 Conference	01/03
Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference	29/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Coya Therapeutics, Inc.

Actions

COYA

US22407B1089

Autres langues

Filtres